Administrative and Congressional Activity Related to the 340B Drug Pricing Program Likely To Continue in 2019

Over the last several years, the 340B drug pricing program has been the subject of intense political scrutiny. Perhaps in no other year has the program and its participants seen more administrative and Congressional activity than in 2018, with policymakers in both Congress and the Administration considering, and in some cases implementing, changes to the 340B program with significant financial and operational implications for covered entity participants. Recent developments suggest that the program will continue to be a lightning rod in 2019 as the political debate around the size, scope, and intent of the program is all but certain to continue.